Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

William Dreiss

Family Medicine Tyler, TX Medical Doctor

NPI 1932493624 CMS profile 902320

11937 US Highway 271, Tyler, TX 75708

Open in the dashboard

General payments

$12,368

257 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Dreiss of Tyler, TX is reported in the CMS Open Payments database as having received $12,368 across 257 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,353 116
2024 General $1,634 45
2023 General $6,205 78
2022 General $1,161 17
2021 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Dreiss
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to William Dreiss were reported at $3,353. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year William Dreiss Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $15 $137 $35–$551 $132
2022 $1,161 $137 $37–$512 $149
2023 $6,205 $149 $42–$545 $160
2024 $1,634 $156 $44–$560 $164
2025 $3,353 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $2,283 46 payments
  2. Boston Scientific Corporation $2,073 51 payments
  3. Saluda Medical Americas, Inc. $1,965 18 payments
  4. Medtronic, Inc. $1,797 37 payments
  5. Relievant Medsystems, Inc. $836 11 payments
  6. Nalu Medical, Inc. $762 35 payments
  7. Nevro Corp. $529 12 payments
  8. Globus Medical, Inc. $435 7 payments
  9. Wenzel Spine, Inc. $372 2 payments
  10. Vertos Medical, Inc. $329 5 payments
  11. Other $985 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,267 241 payments
  2. Travel and Lodging $3,100 16 payments
Products named General payments · program years 2021–2025
  1. Evoke SCS $1,818 14 payments
  2. PROCLAIM Neuromodulation $1,341 11 payments
  3. Intracept Pain $889 13 payments
  4. VANTA ADAPTIVESTIM $836 12 payments
  5. Nalu Neurostimulation System $762 35 payments
  6. INTELLIS ADAPTIVESTIM $650 14 payments
  7. Intracept Pain $627 5 payments
  8. Senza $529 12 payments
  9. PROCLAIM Structural Heart $498 13 payments
  10. WaveWriter Alpha Prime 16 $415 20 payments
  11. Other $4,058 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

3,414

Median for Family Practice: 1,826

Drug cost

$86,871

Median for Family Practice: $120,094

Branded share of claims

67.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,648 $45,741
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 482 $15,180
Buprenorphine Generic 24 $5,520
Pregabalin Generic 127 $2,888
Fentanyl Generic 34 $2,362
Morphine Sulfate Er Morphine Sulfate Brand 103 $2,298
Morphine Sulfate Generic 83 $2,213
Acetaminophen-Codeine Acetaminophen With Codeine Brand 79 $2,145
Gabapentin Generic 166 $1,802
Tramadol Hcl Generic 201 $1,277

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 103 billing codes

Paid by Medicare

$253,630

Of which drugs: $154

Medicare patients

487

Average age 73

Services billed

3,586

289 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Ischemic heart disease 37%
Depression 36%
Chronic kidney disease 28%
COPD 26%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 24 641 $66
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 37 377 $34

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record